Lucid Capital initiated coverage of Genelux (GNLX) with a Buy rating and $10 price target Genelux is a late clinical-stage biotechnology company focused on utilizing oncolytic viral immunotherapies for the treatment of cancer, the analyst tells investors in a research note. The firm sees a “low hanging fruit” opportunity for lead candidate Olvi-Vec in platinumresistant/refractory ovarian cancer.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNLX: